The sales of cardiovascular system medicines in Australia experienced notable fluctuations over the years. The market saw a significant decline from 2013, reaching its lowest in 2019 before initiating a recovery phase. The year 2020 marked a turning point, with sales increasing yearly thereafter. By 2023, sales stood at $1.81 billion, representing a year-on-year growth of 7.7% and a five-year CAGR of 5.83%. Forecasts indicate continued robust growth, with the market expected to reach $2.43 billion by 2028, reflecting a forecasted five-year CAGR of 4.69%.
Future trends to watch for include advancements in cardiovascular treatments and technology, increased healthcare spending, and the aging population, which may further drive market growth.
